Sanofi misses income estimate despite Dupixent effect

1 February 2024
sanofi_large

French pharma major Sanofi (Euronext: SAN) was trading 4% lower late Thursday after presenting its fourth quarter and full year 2023 financial results.

Sales for the fourth quarter grew by nearly 2% to 10.92 billion euros ($11.82 billion), while adjusted operating income fell 5% to 2.58 billion euros, where 2.77 billion euros had been forecast by analyts in a poll on the company's website.

"Our R&D transformation has reached an inflection point on the road to industry leadership in immunology"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical